KBR:NYSEKBR, Inc. Analysis
Data as of 2026-04-12 - not real-time
$36.67
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Fundamentally, KBR shows a resilient earnings profile despite a recent dip in revenue. The latest quarter delivered an earnings‑per‑share beat and modest margin expansion in its mission‑tech segment, while the dividend payout remains modest and well‑covered by cash flow. Valuation metrics such as a low price‑to‑earnings multiple relative to industry peers and a strong return on equity suggest the stock is priced attractively. However, the company carries a high debt‑to‑equity ratio, which tempers the upside.
From a technical perspective, the share price is trading below its short‑ and medium‑term moving averages, indicating a bearish bias. Yet the MACD histogram has turned positive and the RSI sits in a neutral zone, hinting at a potential bottoming process near the identified support level. Analyst consensus targets imply notable upside, and the dividend yield adds a defensive layer, making the stock a candidate for a rebound if momentum re‑asserts.
From a technical perspective, the share price is trading below its short‑ and medium‑term moving averages, indicating a bearish bias. Yet the MACD histogram has turned positive and the RSI sits in a neutral zone, hinting at a potential bottoming process near the identified support level. Analyst consensus targets imply notable upside, and the dividend yield adds a defensive layer, making the stock a candidate for a rebound if momentum re‑asserts.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near technical support
- neutral momentum indicators
- stable trading volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- analyst price targets indicating upside
- low valuation multiples versus peers
- sustainable dividend yield
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- strong ROE and cash flow generation
- strategic investments in AI and mission‑critical tech
- defensive exposure to government contracts
Key Metrics & Analysis
Financial Health
Revenue Growth-10.60%
Profit Margin5.33%
P/E Ratio10.5
ROE30.75%
ROA5.36%
Debt/Equity191.73
P/B Ratio3.1
Op. Cash Flow$524.0M
Free Cash Flow$298.2M
Industry P/E30.9
Technical Analysis
TrendBearish
RSI40.7
Support$35.62
Resistance$39.70
MA 20$37.25
MA 50$39.67
MA 200$44.05
MACDBullish
VolumeStable
Fear & Greed Index87.09
Valuation
Fair Value$13.02
Target Price$51.75
Upside/Downside41.12%
GradeUndervalued
TypeBlend
Dividend Yield1.80%
Risk Assessment
Beta0.82
Volatility25.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.